Printer Friendly

FOREST LABORATORIES ANNOUNCES FILING OF NEW DRUG APPLICATION FOR PROSTAGLANDIN E2 PESSARY

 NEW YORK, Jan. 3 /PRNewswire/ -- Forest Laboratories, Inc. (AMEX: FRX), an international pharmaceutical manufacturer and marketer, announced today that a New Drug Application for its prostaglandin E2 pessary had been filed with the Food and Drug Administration. Forest acquired the exclusive U.S. marketing rights to the pessary from Pharmasciences, Inc. of Pennsylvania in October 1993.
 The prostaglandin pessary is a polymer based intravaginal device infused with prostaglandin E2 which is used for cervical ripening in the induction of labor. The pessary is unique in its highly predictable timed release of drug and its retrieval device which permits maximum flexibility in its use.
 -0- 1/3/94
 /CONTACT: Kenneth E. Goodman, vice president-finance of Forest, 212-421-7850/
 (FRX)


CO: Forest Laboratories, Inc. ST: New York IN: MTC SU:

GK -- NY047 -- 8543 01/03/94 14:12 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 3, 1994
Words:136
Previous Article:STONE & WEBSTER ENGINEER, CM FOR HYDRO FACILITY
Next Article:AMEX TO LAUNCH OPTIONS ON PLUM CREEK TIMBER COMPANY, L.P.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters